Clofazimine
From Ganfyd
(Difference between revisions)
(sort of a dermatology cure all) |
Current revision (12:19, 10 January 2010) (view source) m (image) |
||
| Line 1: | Line 1: | ||
| - | {{PharmacologyBox}} | + | {{PharmacologyBox|||[[image:{{PAGENAME}}Molecule.png|thumb|{{PAGENAME}} Molecule]]|[[image:{{PAGENAME}}.png|center]]|||}} |
A riminophenazine dye and anti-[[leprosy]] drug with anti-inflammatory properties that is provided free for its major indication. The antiapoptic p53 interacting protein MDM2 binds to it so it is being studied further. It is also used with variable evidence base strength as a second line agent in recurrent aphthous stomatitis<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=19699111 de Abreu MA, Hirata CH, Pimentel DR, Weckx LL. Treatment of recurrent aphthous stomatitis with clofazimine. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2009 Nov; 108(5):714-21.]<small>([http://dx.doi.org/10.1016/j.tripleo.2009.05.009 Link to article] – subscription may be required.)</small></ref>, other myocobacterial infections, [[rhinoscleroma]], [[pyoderma gangrenosum]], [[necrobiosis lipoidica]], [[acne]], pustular [[psoriasis]], and discoid [[lupus]] erythematosus<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=7829710 Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. Journal of the American Academy of Dermatology. 1995 Feb; 32(2 Pt 1):241-7.]</ref>. | A riminophenazine dye and anti-[[leprosy]] drug with anti-inflammatory properties that is provided free for its major indication. The antiapoptic p53 interacting protein MDM2 binds to it so it is being studied further. It is also used with variable evidence base strength as a second line agent in recurrent aphthous stomatitis<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=19699111 de Abreu MA, Hirata CH, Pimentel DR, Weckx LL. Treatment of recurrent aphthous stomatitis with clofazimine. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2009 Nov; 108(5):714-21.]<small>([http://dx.doi.org/10.1016/j.tripleo.2009.05.009 Link to article] – subscription may be required.)</small></ref>, other myocobacterial infections, [[rhinoscleroma]], [[pyoderma gangrenosum]], [[necrobiosis lipoidica]], [[acne]], pustular [[psoriasis]], and discoid [[lupus]] erythematosus<ref>[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=7829710 Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. Journal of the American Academy of Dermatology. 1995 Feb; 32(2 Pt 1):241-7.]</ref>. | ||
{{refsec}} | {{refsec}} | ||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
Current revision
rINN: Clofazimine
Pharmacological Information
Pharmacology Images
Clofazimine in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
A riminophenazine dye and anti-leprosy drug with anti-inflammatory properties that is provided free for its major indication. The antiapoptic p53 interacting protein MDM2 binds to it so it is being studied further. It is also used with variable evidence base strength as a second line agent in recurrent aphthous stomatitis[1], other myocobacterial infections, rhinoscleroma, pyoderma gangrenosum, necrobiosis lipoidica, acne, pustular psoriasis, and discoid lupus erythematosus[2].
References
- ↑ de Abreu MA, Hirata CH, Pimentel DR, Weckx LL. Treatment of recurrent aphthous stomatitis with clofazimine. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2009 Nov; 108(5):714-21.(Link to article – subscription may be required.)
- ↑ Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. Journal of the American Academy of Dermatology. 1995 Feb; 32(2 Pt 1):241-7.
